What changed 10-K

Item 2. Properties

2026-03-26 compared with 2025-02-28 · 7 added, 8 removed, 0 unchanged (100% of the section changed)

and Facilities

lease a 14,507 square foot manufacturing facility in Irvine, California under a lease that expires on September 30, 2027.

is designed expressly for the manufacture of biologic vascular grafts and is equipped for research and development, prototype fabrication,

cGMP manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices.

We believe that our facilities

are sufficient for the near future as there is present capacity to manufacture up to approximately 24,000 venous valves per year to meet

potential market demands.

and Safety Disclosure

of December 31, 2025, we lease a 14,507 square foot manufacturing facility in Irvine, California under a lease that expires on September

Our facility is designed expressly for the manufacture of biologic vascular grafts and is equipped for research and development,

prototype fabrication, cGMP manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices.

that our facilities are sufficient for the near future as there is present capacity to manufacture up to approximately 20,000 venous

valves per year to meet potential market demands.

Legal Proceedings

Mine and Safety Disclosures

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.